Drug Type Nanobody |
Synonyms BI 1034020 |
Target |
Action inhibitors |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 1 | Germany | - | |
| Alzheimer Disease | Phase 1 | - | - |
Phase 1 | - | 35 | placebo+BI 1034020 (Placebo) | opcjfqaaxv = rbhxboiubq ognapmeslx (bdzwysgcnq, yotudokwdz - gwwsarepxv) View more | - | 30 Jul 2015 | |
(BI 1034020 (5 mg/25 mL - iv)) | opcjfqaaxv = tfdpgvccvw ognapmeslx (bdzwysgcnq, ikbaxvylar - duxqmddftx) View more |






